Have you suffered losses in Vesta Medical Series B Preferred shares (dba Vestara)? If so, the securities attorneys of The White Law Group may be able to help you recover your losses through FINRA arbitration.
First offered in June 2007, Vestara is a private placement investment in medical equipment technology. In April 2008, Vestara launched EcoRexNS(TM) to reduce medical waste. According to the companies own announcement, the EcoRexNS™ incorporates barcode technology, already widely used in hospitals to track drug utilization and prevent medication errors, and a proprietary, continuously updated database of more than 140,000 National Drug Code (NDC) products, to instantly categorize waste medicines.
Notwithstanding the launch of the EcoRex system, it appears that private placement investments in Vestara have not performed to expectations and that investors have sufferedd large losses.
The White Law Group is investigating the liability that brokerage firms may have for recommmending the investment.
Financial advisors and broker-dealers have a duty to their clients to perform the necessary due diligence on an investment before offering it for sale to their clients and to ensure that any investment recommendation that is made is suitable in light of the client’s age, investment experience, net worth, and investment objectives. Given the performance of the Vestara private placement, it appears that brokerage firms may have downplayed the risks of the offering.
If you invested in Vesta Medical Series B preferred shares (Vestara Medical) and are interested in your litigation options, please call the securities attorneys of The White Law Group at 312/238-9650 for a free consultation.
The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois and Boca Raton, Florida.
For more information on The White Law Group, visit https://www.whitesecuritieslaw.com.